Cellmid 2018 Annual Report 23
^ The negative share-based payment is due to a reversal of share based payment previously
recognised. Refer to equity-based compensation for details.
2017 Cash salary Employee Employee
fees entitlements entitlements Superannuation Options Total
$ $ $ $ $ $
Directors
Non-executive directors
David King 65,000 - - 6,175 - 71,175
Bruce Gordon 50,000 - - - - 50,000
Fintan Walton 50,000 - - - - 50,000
Total non-executive directors 165,000 - - 6,175 - 171,175
Executive directors and key management
Maria Halasz 428,538 18,457 4,470 22,800 (52,781)^ 421,484
593,538 18,457 4,470 28,975 (52,781) 592,659
Post-
Long-term employment Share-based
Short-term beneï¬ts beneï¬ts beneï¬ts payments
Directors’ and Key Management Personnel (KMP) shareholdings
The number of shares held in the Group during the ï¬nancial year by each Director and (KMP) of Cellmid Limited, including their
related parties, are set out below.
*On 23 November 2017, the Group completed a twenty to one share consolidation.
Balance at Received Other Other Balance
beginning as part of changes Pre changes Post at end of
of year remuneration Consolidation Consolidation* Consolidation year
2018
David King 24,000,000 - 4,000,000 (26,600,000) - 1,400,000
Maria Halasz 25,073,025 - 2,250,000 (25,956,874) 207,500 1,573,651
Bruce Gordon 1,500,000 - - (1,425,000) - 75,000
Fintan Walton 800,000 - 500,000 (1,235,000) - 65,000
Martin Cross - - 900,000 (855,000) - 45,000
Dennis Eck - - - - 2,700,000 2,700,000
2017
David King 22,500,000 - 1,500,000 - - 24,000,000
Maria Halasz 24,222,600 - 850,425 - - 25,073,025
Bruce Gordon 500,000 - 1,000,000 - - 1,500,000
Fintan Walton 300,000 - 500,000 - - 800,000